Literature DB >> 2080228

Enhanced interleukin production after long-term administration of erythromycin stearate.

E Kita1, M Sawaki, F Nishikawa, K Mikasa, Y Yagyu, S Takeuchi, K Yasui, N Narita, S Kashiba.   

Abstract

The effects of erythromycin stearate (10 mg/kg/day) were studied on productions of interleukin (IL)-1 and -2 in mice after a long-term treatment. A 28-day treatment resulted in higher levels of IL-1 production by macrophages and of IL-2 production by splenocytes, while a 7-day treatment did not increase them. T-cell growth factor activity of IL-2 preparation prepared on day 28 of treatment as determined by HT-2 cell proliferation was reduced by about 40% in the presence of anti-murine IL-4 monoclonal antibodies, while control IL-2 activity was not reduced. Furthermore, a 28-day treatment with erythromycin stearate increased concanavalin A-induced blastogenesis of splenocytes significantly. These results suggest that long-term treatment with erythromycin stearate can stimulate host defense by increasing interleukin production.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2080228     DOI: 10.1159/000138716

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  12 in total

1.  Differential modulatory effects of clarithromycin on the production of cytokines by a tumor.

Authors:  K Sassa; Y Mizushima; M Kobayashi
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

Review 2.  Antibiotics in asthma.

Authors:  David A Beuther; Richard J Martin
Journal:  Curr Allergy Asthma Rep       Date:  2004-03       Impact factor: 4.806

3.  Efficacy of erythromycin lactobionate for treating Pseudomonas aeruginosa bacteremia in mice.

Authors:  Y Hirakata; M Kaku; K Tomono; K Tateda; N Furuya; T Matsumoto; R Araki; K Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

4.  Therapeutic effect of clarithromycin on a transplanted tumor in rats.

Authors:  K Sassa; Y Mizushima; T Fujishita; R Oosaki; M Kobayashi
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

5.  Direct evidence for antipseudomonal activity of macrolides: exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin, and azithromycin.

Authors:  K Tateda; Y Ishii; T Matsumoto; N Furuya; M Nagashima; T Matsunaga; A Ohno; S Miyazaki; K Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

6.  Quorum-sensing antagonistic activities of azithromycin in Pseudomonas aeruginosa PAO1: a global approach.

Authors:  Yusuf Nalca; Lothar Jänsch; Florian Bredenbruch; Robert Geffers; Jan Buer; Susanne Häussler
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

Review 7.  Immunomodulating effects of antibiotics: literature review.

Authors:  B Van Vlem; R Vanholder; P De Paepe; D Vogelaers; S Ringoir
Journal:  Infection       Date:  1996 Jul-Aug       Impact factor: 3.553

8.  Effects of sub-MICs of erythromycin and other macrolide antibiotics on serum sensitivity of Pseudomonas aeruginosa.

Authors:  K Tateda; Y Hirakata; N Furuya; A Ohno; K Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

9.  Immunomodulatory effects of three macrolides, midecamycin acetate, josamycin, and clarithromycin, on human T-lymphocyte function in vitro.

Authors:  K Morikawa; F Oseko; S Morikawa; K Iwamoto
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

10.  Potential effects of erythromycin on host defense systems and virulence of Pseudomonas aeruginosa.

Authors:  Y Hirakata; M Kaku; R Mizukane; K Ishida; N Furuya; T Matsumoto; K Tateda; K Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.